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Purpose: Using real-world data, this study com-
pares inpatient length of stay (LOS) and costs for
patients with a primary diagnosis of pulmonary
embolism (PE) initiating treatment with oral anti-
coagulation with rivaroxaban versus warfarin.
Methods: Hospitalizations from MarketScan’s
Hospital Drug Database were selected from Novem-
ber 1, 2012, through December 31, 2013, for adults
with a primary diagnosis of PE initiating treatment
with rivaroxaban or warfarin. Warfarin patients were
matched 1:1 to rivaroxaban patients using exact and
propensity score matching. Hospital LOS, treatment
patterns, and hospitalization costs were evaluated.
Findings: Matched cohorts included 751
rivaroxaban-treated patients and 751 warfarin-treated
patients. Adjusted mean LOS was 3.77 days for
rivaroxaban patients (95% CI, 3.66–3.87 days) and
5.48 days for warfarin patients (95% CI, 5.33–5.63
days; P o .001). Mean (SD) LOS was shorter for
patients taking rivaroxaban whether admission was for
provoked PE (rivaroxaban: 5.2 [5.1] days; warfarin: 7.0
[6.5] days; P o .001) or unprovoked PE (rivaroxaban:
3.4 [2.3] days; warfarin: 5.1 [2.7] days; P o .001).
Mean (SD) days from ﬁrst dose to discharge were 2.5
(1.7) (rivaroxaban) and 4.0 (2.9) (warfarin) when
initiated with parenteral anticoagulants (P o .001)
and 2.7 (1.7) (rivaroxaban) and 4.0 (2.2) (warfarin)
without parenteral anticoagulants (P o .001). The
rivaroxaban cohort incurred signiﬁcantly lower unad-
justed mean (SD) hospitalization costs (rivaroxaban:2496$8473 [$9105]; warfarin: $10,291 [$9185]; Po .001),
conﬁrmed by covariate adjustment with generalized
linear modeling estimating predicted mean hospital-
ization costs of $8266 for rivaroxaban patients (95%
CI, $7851–$8681) and $10,511 for warfarin patients
(95% CI, $10,031–$10,992; P o .001).
Implications: patients with PE treated with rivar-
oxaban incurred signiﬁcantly lower hospitalization
costs by $2245 per admission compared with patients
treated with warfarin, which was attributable to cost
offsets from 1.71 fewer days of stay in the hospital.
(Clin Ther. 2016;38:2496–2503) & 2016 The Au-
thors. Published by Elsevier HS Journals, Inc.
Key words: hospitalization costs, length of stay,
pulmonary embolism, rivaroxaban, warfarin.INTRODUCTION
Pulmonary embolism (PE) is a common and some-
times fatal form of venous thromboembolism (VTE).
An estimated 650,000 individuals are affected in the
United States each year, with approximately 20% to
25% mortality within the ﬁrst day of diagnosis and
410% at mortal risk during the ﬁrst month after
diagnosis, imposing a substantial economic burden onVolume 38 Number 11
J.M. Margolis et al.the US health care system, with estimated annual costs
exceeding $1.5 billion.1–3
Clinical practice treatment guidelines recommend
short-term treatment with parenteral anticoa-
gulants, such as low-molecular-weight heparin, fon-
daparinux, or unfractionated heparin, either alone
or with an oral vitamin K antagonist (VKA).4 Use of
VKA anticoagulants, most commonly warfarin,
typically start concurrently with or shortly after
initiating heparin therapy. Despite proven efﬁcacy
of VKA anticoagulants in preventing recurrence,
they have several clinical limitations. Their onset of
action can take several days, they have numerous
chemical interactions, and their narrow therapeutic
range requires regular laboratory monitoring for
anticoagulation optimization.5–7
Alternatives to VKAs for oral anticoagulant ther-
apy available in the United States include the direct
thrombin inhibitor dabigatran and the factor Xa
inhibitors rivaroxaban, apixaban, and edoxaban.
They exhibit a quicker onset of action, have fewer
food and drug interactions, and do not require routine
laboratory monitoring.8
Rivaroxaban is an oral inhibitor of factor Xa, with
onset of action 2 to 4 hours after initiation and no
requirement for coagulation monitoring.9 Post hoc
analyses of the EINSTEIN clinical trials revealed
equivalent efﬁcacy and signiﬁcantly shorter hospital
stays, with mean reductions in stay of 1.6 days in
rivaroxaban-treated patients with VTE and 1.7 days for
rivaroxaban-treated patients with PE than those with
standard-of-care treatment.10,11 Little is known in real-
world clinical practice about the length of hospital stay
and economic burden attributable to hospitalization in
patients with PE initiating treatment with inpatient oral
anticoagulation with rivaroxaban versus VKAs.
The primary objective of this study was to augment
the information learned in the clinical trial setting
by examining hospital length of stay (LOS), treatment
patterns, and hospitalization costs in real-world
practice using a data set derived from a large and
geographically diverse sample of US hospitals,
comparing patients hospitalized with a primary PE
diagnosis who were receiving rivaroxaban versus
warfarin oral anticoagulation therapy during their
hospital stay. This brief report is a subset analysis of
a larger VTE study that focused on matched cohorts
of 751 patient admissions with a primary diagnosis
of PE.November 2016METHODS
The data source was completed admission records
from the Truven Health MarketScan Hospital Drug
Database (HDD) from November 1, 2012, through
December 31, 2013, including inpatient diagnoses,
procedures, and drugs administered, derived from
the ordering and billing systems of 4600 geograph-
ically and demographically diverse US hospitals.
This study used only deidentiﬁed patient records in
full compliance with the Health Insurance Portabil-
ity and Accountability Act of 1996. Because it
did not involve collection, use, or transmittal of
individually identiﬁable data, institutional review
board approval to conduct this study was not
required.
Completed admissions with a primary diagnosis of
PE (International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation [ICD-9-CM] diagnosis
code 415.1x) were selected from the HDD from
November 1, 2012, through December 31, 2013, for
adults receiving rivaroxaban or warfarin during hos-
pitalization. Low-molecular-weight heparin or unfrac-
tionated heparin therapy may have been received
before patients received rivaroxaban or warfarin.
Patients were excluded from analysis if a hospital
admission record was found within 12 months before
the index date with a VTE diagnosis in any position to
increase the likelihood of our admissions focusing on
a patient’s initial PE event. Hospitalizations were also
excluded for patients receiving both rivaroxaban and
warfarin, those receiving either apixaban or dabiga-
tran etexilate mesylate (edoxaban was not yet avail-
able in the United States), patientso18 years old, and
those who were pregnant.
Patients receiving warfarin were matched 1:1 to
patients receiving rivaroxaban using a combination of
exact matching on the primary PE diagnoses followed
by propensity score matching using a logistic regres-
sion model to predict the probability of initiating
rivaroxaban treatment. The independent variables
included patient demographic characteristics (age,
sex, payer, admission year, admission source, admis-
sion to intensive care unit), hospital demographic
characteristics (geographic location, teaching, urban,
bed size), comorbidity index, and clinical character-
istics reﬂecting speciﬁc baseline comorbidities (ane-
mia, arrhythmia, cancer, chronic obstructive
pulmonary disease, diabetes, drug abuse, dyslipide-
mia, esophageal disorders, heart failure, hypertension,2497
Clinical Therapeuticshypothyroidism, ischemic heart disease, obesity, renal
disease). The balance achieved in the matching proce-
dure was assessed by the standardized mean differ-
ences of the covariates in the logistic regression model.
A covariate was considered balanced between cohorts
if the standardized mean difference was not
410%.12,13
Hospital LOS (days from admission to discharge),
days from admission to ﬁrst dose, days from ﬁrst dose
to discharge, and hospitalization costs by service
categories, including room costs, inpatient medication
costs, laboratory tests, procedures, and other services,
were reported. LOS results were further stratiﬁed into
provoked PE versus unprovoked PE, with provoked
PE deﬁned as patients with a fracture diagnosis,
a major surgical procedure, selected drugs (oral
contraceptives, estrogens, progestins, selective
estrogen receptor modulators, aromatase inhibitors,
or erythropoiesis-stimulating agents), a postpartum
diagnosis, or a malignant neoplasm diagnosis.4
Costs for all inpatient hospital services were
reported, categorized according to room costs,
inpatient medications, laboratory tests, procedures,
all other inpatient services (eg, imaging, respiratory
therapy, other therapy, medical or surgical services,
medical or surgical supplies, operating room, other),
and total. Hospital costs were calculated by applying
the Centers for Medicare & Medicaid Services ratios
of costs to charges at both the hospital and
department levels and adjusted to 2015 US dollars
using the Medical Care Component of the Consumer
Price Index. Baseline demographic and clinical
characteristics, including selected comorbidities and
concomitant medications, were also recorded.
Dependent and independent variables were sum-
marized descriptively, with observed differences be-
tween treatment groups tested using χ2 tests for
categorical variables and t tests for continuous varia-
bles. Generalized linear models (GLMs) were ﬁtted to
the main outcomes of LOS (negative binomial, log
link regression), days from ﬁrst dose to discharge
(negative binomial, log link regression), and hospital-
ization costs (log link function and γ error distribu-
tion), adjusting for demographic and clinical
characteristics. P o .05 was set as the threshold for
statistically signiﬁcant differences. Statistical analyses
were conducted using SAS software, version 9.4 (SAS
Institute Inc, Cary, North Carolina).2498RESULTS
From an initial sampling of 22,781 patients admitted
with a primary diagnosis of VTE, 22,009 patients
lacked a prior VTE hospitalization, including 1879
patients treated with rivaroxaban and 16,557 treated
with warfarin. Application of the remaining selection
criteria yielded a ﬁnal cohort of 751 patients treated
with rivaroxaban with a primary diagnosis of PE and
subsequently matched 1:1 with patients treated with
warfarin, producing ﬁnal matched cohorts, each in-
cluding 751 patients with primary PE. The 2 treat-
ment cohorts were well balanced for demographic and
clinical characteristics after matching (Table).
Patients with primary PE treated with rivaroxaban
had signiﬁcantly shorter observed mean (SD) LOS
than patients treated with warfarin (rivaroxaban
patients: 3.8 [3.2] days; warfarin patients: 5.4 [3.9]
days; P o .001) (Figure 1). GLM modeling of LOS,
adjusting for demographic and clinical characteristics,
conﬁrmed these results, with an adjusted overall mean
LOS for PE of 3.77 days (95% CI, 3.66–3.87 days)
for rivaroxaban and 5.48 days (95% CI, 5.33–5.63
days) for warfarin for an adjusted difference of 1.71
fewer days per admission for the rivaroxaban cohort
(Po .001). We further observed that the rivaroxaban
cohort had signiﬁcantly shorter mean LOS than the
warfarin cohort whether the PE was considered
provoked (rivaroxaban: 5.2 [5.1] days; warfarin: 7.0
[6.5] days; P o .001) or unprovoked (rivaroxaban:
3.4 [2.3] days; warfarin: 5.1 [2.7] days; P o .001)
(Figure 1).
The proportion of patients initiating treatment with
parenteral anticoagulants was 66% in both treatment
cohorts; however, the observed mean (SD) time from
admission to ﬁrst treatment dose was generally longer
for patients treated with rivaroxaban (with parenteral
anticoagulants: rivaroxaban: 2.2 [1.7] days; warfarin:
1.8 [1.8] days; P o .001; without parenteral anti-
coagulants: rivaroxaban: 1.0 [1.6] days; warfarin: 0.4
[0.7] days; P o .001). The observed mean (SD) time
from ﬁrst treatment dose to discharge was signiﬁcantly
shorter for rivaroxaban-treated compared with
warfarin-treated patients regardless of treatment with
or without parenteral anticoagulants (with parenteral
anticoagulants: rivaroxaban: 2.5 [1.7] days; warfarin:
4.0 [2.9] days; P o .001; without parenteral anti-
coagulants: rivaroxaban: 2.7 [1.7] days; warfarin: 4.0
[2.2] days; P o .001). A similar pattern was observedVolume 38 Number 11
Table. Patient and hospital characteristics of hospitalized patients with pulmonary embolism treated with
rivaroxaban versus warfarin: final study cohorts meeting all selection criteria and propensity score
matching*
Characteristic Rivaroxaban (n ¼ 751) Warfarin (n ¼ 751) P
Age, mean (SD), y 63.6 (16.5) 63.9 (16.7) 0.788
Age group 0.363
18-24 y 0.9 1.6
25-34 y 4.8 4.3
35-44 y 8.3 8.9
45-54 y 16.0 12.4
55-64 y 17.2 19.0
65-74 y 23.6 22.5
Z75 y 29.3 31.3
Sex 0.836
Male 47.9 47.4
Female 52.1 52.6
Principal payer 0.709
Private insurance 35.0 37.4
Medicare 54.7 54.3
Medicaid 4.1 3.3
Other 6.1 4.9
Hospital type 0.946
Teaching 17.2 17.3
Nonteaching 82.8 82.7
Hospital setting 40.99
Urban 86.6 86.6
Rural 13.4 13.4
Licensed bed size 0.740
1-199 beds 22.9 23.4
200-299 beds 18.1 19.0
300-499 beds 28.1 25.6
Z500 beds 30.9 32.0
Discharge status 0.078
Home/home health 88.0 86.7
Transferred 10.9 13.0
Other 1.1 0.3
No. of diagnoses, mean (SD)† 9.8 (4.6) 10.0 (4.5) 0.464
Comorbid conditions‡
Hypertension 61.1 62.3 0.633
Dyslipidemia 39.0 40.5 0.562
Ischemic heart disease or angina 21.6 20.9 0.752
COPD 21.2 21.3 0.950
Cardiac arrhythmia 20.5 21.0 0.799
Diseases of the esophagus 19.7 20.5 0.699
Diabetes 19.6 18.1 0.468
Anemia 18.6 20.1 0.473
(continued)
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Table. (continued).
Characteristic Rivaroxaban (n ¼ 751) Warfarin (n ¼ 751) P
Overweight or obese 18.2 21.6 0.106
Renal disease 14.5 15.0 0.771
Nondependent abuse of drugs 13.8 13.7 0.940
Acquired hypothyroidism 13.0 10.9 0.204
Heart failure 12.1 11.5 0.689
Malignant cancer 8.9 8.7 0.855
Cardiometabolic medications
β-blockers 39.9 41.5 0.529
Antiplatelets 38.9 41.1 0.371
Statins 35.0 36.1 0.666
Diuretics 28.6 34.8 0.011
ACE inhibitors 27.3 27.2 0.954
Calcium channel blockers 22.5 22.2 0.901
ARBs 10.3 10.7 0.800
Thrombolytics 9.1 13.7 0.004
ARBs ¼ angiotensin II receptor blockers; COPD¼ chronic obstructive pulmonary disease; PE ¼ pulmonary embolism.
*Data are presented as percentage of patients unless otherwise indicated.
†Unique 3-digit International Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation (ICD-9-CM) codes.
‡Comorbid conditions reported in o5% of these admissions included peripheral vascular disease, cerebrovascular disease,
hepatic disease, major bleed, abdominal surgery, orthopedic surgery, and inﬂammatory bowel disease.
Clinical Therapeuticsin comparing provoked and unprovoked PE treatment
cohorts. Modeling mean time from ﬁrst dose to
discharge conﬁrmed the observed overall results with
2.57 days (95% CI, 2.53–2.61 days) for rivaroxaban
and 4.01 days (95% CI, 3.95–4.08 days) for warfarin
for an adjusted mean difference of 1.44 fewer days for
rivaroxaban-treated patients (P o .001).
The rivaroxaban cohort had signiﬁcantly lower
observed total mean (SD) hospitalization costs
($8473 [$9105] vs $10,291 [$9185]; P o .001) and
room charges ($2162 [$2556] vs $3239 [$3182]; Po
.001) (Figure 2). Overall mean (SD) inpatient
medication costs were not statistically different
between treatment groups (rivaroxaban: $679
[$1554]; warfarin: $800 [$1313]; P ¼ 0.101) despite
higher oral anticoagulant cost for rivaroxaban-treated
patients (rivaroxaban: $22 [$29]; warfarin: $5 [$9];
Po .001). Other inpatient costs for rivaroxaban-treated
and warfarin-treated patients included laboratory tests
(rivaroxaban: $444 [$600]; warfarin: $534 [$485];
P ¼ .001), procedures (rivaroxaban: $249 [$1239];2500warfarin: $156 [$626]; P ¼ 0.068), and other in-
patient services (rivaroxaban: $4881 [$5298]; warfarin:
$5400 [$4759]; P ¼ 0.046). (Component mean costs
add to less than the total mean hospitalization costs
attributable to ratios of costs to charges rounding.)
GLM modeling results for total hospital costs,
adjusting for demographic and clinical characteristics,
conﬁrmed the statistically signiﬁcant differences in mean
costs between the matched rivaroxaban and warfarin
cohorts. Predicted mean total hospitalization costs for
the rivaroxaban cohort were $8266 (95% CI, $7851–
$8681; median, $6515) and $10,511 (95% CI,
$10,031–$10,992; median, $8721) for warfarin-treated
patients, a signiﬁcant adjusted mean difference of $2245
between cohorts per admission.DISCUSSION
This study found that admissions for treatment of PE
were signiﬁcantly shorter by 1.71 days, with fewer
days from ﬁrst dose to discharge, and had signiﬁcantlyVolume 38 Number 11
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November 2016in LOS was consistent across the provoked and
unprovoked PE patient strata. This difference, found
in real-world primary PE hospitalizations, closely
aligns with the EINSTEIN clinical trials.10,11 The
subanalysis of North American EINSTEIN patients
found rivaroxaban-treated patients with PE experi-
enced a mean reduction of 1.7 days compared with
enoxaparin- and VKA-treated patients (mean LOS,
4.5 days for the rivaroxaban-treated patients vs 6.2
days for the enoxaparin- and VKA-treated patients;
median, 3 vs 4 days; P o .001).11 The results of the
present study (3.77 vs 5.48 days for the rivaroxaban
vs warfarin groups; median, 3.38 vs 4.99; P o .001)
are important in that they corroborate the clinical trial
ﬁndings in real-world clinical practices across a large
sample of US hospitals.
The lower LOS with initiation of rivaroxaban
treatment (compared with warfarin treatment) may
account for the rivaroxaban cohort’s signiﬁcantly
lower observed total mean hospitalization costs and
room charges ($2162 vs $3239; P o .001). The
predicted mean LOS and total hospitalization costs
per admission (rivaroxaban: mean LOS, 3.77 days;
mean costs, $8266; warfarin: mean LOS, 5.48 days;ban Warfarin
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Clinical Therapeuticsmean costs, $10,511) are well within the range
reported by the 2012 weighted national averages from
the Healthcare Cost and Utilization Project National
Inpatient Sample report (mean LOS, 5.1 days; mean
costs, $10,819 per admission) and a recent study of
costs for patients with PE at Brigham and Women’s
Hospital (mean [SD] LOS, 4.1 [3.2] days; mean [SD]
costs, $8764 [$7236] per admission).14,15 A recent
publication by Dasta et al16 reported a mean total cost
of hospitalization for PE of $9407 and a mean daily
cost of $1735. Our ﬁnding of an estimated $2245
savings for rivaroxaban-treated patients and overall
hospitalization costs are consistent with this ﬁnding.
Two recent observational studies17,18 with primary
end points of LOS corroborated lower LOS for
rivaroxaban-treated patients compared with
warfarin-treated patients, including one study by
Roberts et al17 of patients with a discharge
diagnosis of PE (January 2012 through March
2015) reporting median LOS of 2.7 days fewer for
rivaroxaban-treated patients (N ¼ 76) compared
with patients treated with warfarin plus enoxaparin
(N ¼ 82) and a second study by Desai et al18 of
VTE-treated patients (N ¼ 414) at one institution
with signiﬁcantly shorter LOS for rivaroxaban than
those discharged with a warfarin prescription (3.5 vs
7.0 days, P o .001). Cohort sizes in these studies
were substantially smaller than the present study and
not geographically diverse, which may contribute to
differences in ﬁndings.
These results provide valuable real-world estimates
of hospital utilization and costs among patients with
PE; however, the data source has limitations that
should be noted. The HDD relies on hospital dis-
charge records that may have inaccuracies in coding,
billing, or missing data that could result in measure-
ment error. All data used in this analysis, including
propensity score matching, were limited to those
found during the patient’s hospitalization. Clinical
history before and after hospitalization (eg, prior
medication exposures, such as rivaroxaban or war-
farin, before admission, preadmission comorbidity)
was unavailable. Bias attributable to unknown or
unmeasured covariates cannot be ruled out, especially
because sociodemographic factors (eg, race, socio-
economic status, behaviors such as smoking) were
unavailable. Finally, the HDD is a convenience sample
of contributing US hospitals and, although large, may
not represent the entire US population.2502CONCLUSIONS
In summary, this real-world observational study of
hospital admissions with a primary diagnosis of PE
found that patients initiating oral anticoagulation
therapy with rivaroxaban incurred signiﬁcantly lower
hospitalization costs by $2245 per admission com-
pared with those initiating warfarin, attributable to
the cost offset from 1.71 fewer days of stay in the
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